The Potential Uses of Radiopharmaceuticals in the Pharmaceutical Industry

  • Raymond E. Gibson
  • H. Donald Burns
  • William C. Eckelman


The earliest pharmaceuticals were discovered based on observations of the favorable effects of natural products. Some of the better known examples are digitalis-containing foxglove, quinine-containing cinchona bark, salicylate-containing willow bark, and morphine-containing opium. Many of today’s new drugs are also the result of natural products screening, e.g., avermectins and mevacor. Merck Research Laboratories has recently purchased the rights to certain South American rain forests to continue the search for natural products.


Magnetic Resonance Imaging Contrast Magnetic Resonance Imaging Contrast Agent Brain Blood Flow Positron Emission Tomography Radiotracer Merck Research Laboratory 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bernier DR, Christian PE, Langen JK and Wells LD (1989): Nuclear Medicine Technology and Techniques, St. Louis: C.V. Mosby Co.Google Scholar
  2. Berridge MS, Adler LP, Nelson AD, Cassidy EH, Muzic RF, Bednarczyk EM and Miraldi F (1991): Measurement of human cerebral blood flow with [15O]butanol and positron emission tomography. J Cereb Blood Flow Metab 11: 707–715.CrossRefGoogle Scholar
  3. Bolo NR, Brennan KM, Jones RM and Budinger TF (1987): Fluorodeoxyglucose brain metabolism studies by NMR and PET. Ann NY Acad Sci 508:451–459.CrossRefGoogle Scholar
  4. Bonow RO, Berman DS, Gibbons RJ, Johnson LL, Rumberger JA, Schwaiger M and Wackers FJ (1991): Cardiac positron emission tomography. A report for health professionals from the committee on advanced cardiac imaging and technology of the council on clinical cardiology, American Heart Association, Circulation, 84:447–454.Google Scholar
  5. Bradley RH, Kent TA, Eisenberg HM, Quast MJ, Ward GA, Campbell GA and Hillman G (1989): Middle cerebral artery occlusion in rat studied by magnetic resonance imaging. Stoke 20: 1032–1036.Google Scholar
  6. Eckelman WC, Tweedle M and Welch MJ (1988): NMR enhancement with Gd labeled antibodies. In: Radiolabeled Monoclonal Antibodies for Imaging and Therapy, Srivastat SC, ed. New York: Plenum Press.Google Scholar
  7. Fioravanti C, Burkholder D and Gibson RE (1992): Global cerebral blood flow in rhesus monkeys determined using Tc-99m ECD and planar imaging. J Nucl Med 33 (suppl): 979.Google Scholar
  8. Hattner RS and White DL (1990): Gallium-67/stable gadolinium antagonism: MRI contrast agent markedly alters the normal distribution of gallium-67. J Nucl Med 31: 1844–1846.Google Scholar
  9. Herscovitch P, Markham J and Raichle ME (1983): Brain blood flow measured with intravenous H2 15O: I. Theory and error analysis. J Nucl Med 24: 782–789.Google Scholar
  10. Josephson L, Groman EV, Menz E, Lewis JM and Bengele H (1990): A functionalized supermagnetic iron oxide colloid as a receptor directed MR contrast agent. Magnet Resonance Imgng 8: 637–646.CrossRefGoogle Scholar
  11. Krivokapich J, Barrio JR, Huang SC and Scheiben HR (1990): Dynamic positron tomographic imaging with nitrogen-13 glutamate in patients with coronoary artery disease: comparison with nitrogen-13 ammonia and fluorine-18 fluorodeoxyglucose imaging. J Am Coll Cardiol 16: 1158–1167.CrossRefGoogle Scholar
  12. Krivokapich J, Huang SC, Ratib O and Scheiben HR (1991): Noninvasive detection of functionally significant coronary artery stenoisis with exercise and positron emission tomography. Am Heart J 122:202–211.CrossRefGoogle Scholar
  13. Lauffer RB and Brady TJ (1989): Iron ethylene bis(2-hydroxyphenylglycine) as a hepatobiliary MRI contrast agent. In: Magnetic Resonance Imaging, Partain CL, Price RR, Patton JA, Kulkarni MV and Jasmes AE Jr, eds. Phiadelphia: Saunders.Google Scholar
  14. Loc’h C, Mazèré B and Comar D (1980): A new generator for ionic gallium-68. J Nucl Med 21: 171–173.Google Scholar
  15. Mullani NA, Goldstein RA, Gould KL, Marani SK, Fisher DJ, O’Brien HA Jr and Loberg MD (1983): Myocardial perfusion with Rubidium-82. I. Measurement of extraction fraction and flow with external detectors. J Nucl Med 24: 898–906.Google Scholar
  16. Raichle Me Marten WRW, Herscovitch P, Mintunu MA and Markham J (1983): Brain blood flow measured with intravenous H2 15O: II. Implementation and validation. J Nucl Med 24: 790–798.Google Scholar
  17. Rosen BR, Belliveau JW and Chien D (1989): Perfusion imaging by nuclear magentic resonance. Magnet Resonance Q 5: 263–281.Google Scholar
  18. Vittadini G, Felder E, Tirone P and Lorusso V (1988): B-19036, a potential new hepatobiliary contrast agent for MR proton imaging. Invest Radiol 23 (suppl 1): S246–S248.CrossRefGoogle Scholar
  19. Waldrop MM (1990): The reign of trial and error draws to a close. Science 247: 28–29.CrossRefGoogle Scholar
  20. Weinberg DR, Gibson R, Coppola R, Jones DW, Molchan S, Sunderland T, Berman KF and Reba RC (1991): The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dementia. Arch Neurol 48: 169–176.CrossRefGoogle Scholar

Copyright information

© Birkhäuser Boston 1993

Authors and Affiliations

  • Raymond E. Gibson
    • 1
  • H. Donald Burns
    • 1
  • William C. Eckelman
    • 2
  1. 1.Department of RadiopharmacologyMerck Research LaboratoriesUSA
  2. 2.PET Department, National Institutes of HealthClinical CenterUSA

Personalised recommendations